✨ Free AI Report
C4 Therapeutics, Inc.: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Company Research C4 Therapeutics, Inc.
Company Research

C4 Therapeutics, Inc.: Business Overview, Financials & Competitive Analysis

C4 Therapeutics, Inc. scores 5/10 on the AskCyborg Cyborg Score (Mixed). Early-stage biotech with innovative platform, strong revenue growth, and promising clinical programs offset by significant losses and clinical execution risk. Revenue grew 71.44% in 2024 to $35.58 million, but the company exhibits negative margins with an operating margin of -395.42%. Cash position enables funding into 2027, though Altman Z-Score.

What is C4 Therapeutics, Inc.'s industry? C4 Therapeutics, Inc. (c4therapeutics.com) operates in Biopharmaceuticals - Targeted Protein Degradation. AskCyborg classifies C4 Therapeutics, Inc. under Biopharmaceuticals - Targeted Protein Degradation in its company registry.

C4 Therapeutics is a clinical-stage biopharmaceutical company that develops novel therapeutic candidates to degrade disease-causing proteins. The company is focused on delivering targeted protein degradation science t...

5/ 10Mixed

Cyborg Score thesis

Early-stage biotech with innovative platform, strong revenue growth, and promising clinical programs offset by significant losses...

Read the full analyst-debate transcript →
Industry Biopharmaceuticals - Targeted Protein Degradation
3 named competitors
3 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: September 14, 2026
AI-Verified Research
30+ Page Report

Get the Latest C4 Therapeutics, Inc. Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Analyst-debate audio for C4 Therapeutics, Inc.

AskCyborg analysts argue the bull and bear cases for C4 Therapeutics, Inc. across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
What's in This Report
C4 Therapeutics, Inc. OverviewStrategic ProfileCompetitive LandscapeIndustry ContextKey facts
Get Interactive Report Freeor start reading below

C4 Therapeutics, Inc. Overview

Pro stress-test →

C4 Therapeutics is a clinical-stage biopharmaceutical company that develops novel therapeutic candidates to degrade disease-causing proteins. The company is focused on delivering targeted protein degradation science to create a new generation of medicines that transform patients' lives.

Strategic Profile

Pro stress-test →

The lead product candidate is Cemsidomide, an orally bioavailable MonoDAC degrader of protein in Phase 1/2 clinical trials targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas. The company has strategic collaborations with F. Hoffmann-La Roche Ltd, Biogen MA, Inc., and Merck entities.

Competitive Landscape

Pro stress-test →

Competitors include Nurix Therapeutics, Kymera Therapeutics, Shattuck Labs, Arvinas, Cullinan Therapeutics, and other targeted protein degradation focused companies. C4 Therapeutics differentiates through its Degronimid platform and collaborations with major pharma partners.

Industry Context

C4 Therapeutics, Inc. operates in Biopharmaceuticals - Targeted Protein Degradation.

Key facts

Founded: 2015 · Headquarters: Watertown, Massachusetts · Revenue: $35.58M (2024) · Market cap: $268M

What the analysts stress-tested

The top findings that survived the multi-agent debate for C4 Therapeutics, Inc..

  • Phase 2 MOMENTUM Trial of Cemsidomide initiated in combination with dexamethasone for relapsed/refractory multiple myeloma
  • Q4 2024 revenue of $11.016 million surpassed expectations
+2 more stress-tested counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

  • February 2026Cemsidomide Phase 2 MOMENTUM trial on track to initiate in Q1 2026
  • September 2025Cemsidomide Phase 1 data presented at International Myeloma Society meeting
  • +1 moreTrack every material event for C4 Therapeutics, Inc. as it happens. Explore monitoring →
Get alerted when C4 Therapeutics, Inc. has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

Targeted Protein Degradation PlatformTPD therapeutics for oncology and immunology→IMiD-based DegraderSmall molecule targeted protein degradation→PROTAC TechnologyProteolysis targeting chimeras for cancer→

Compare C4 Therapeutics, Inc. with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

C4 Therapeutics, Inc. operates in Biopharmaceuticals - Targeted Protein Degradation. See how the rest of the sector scores on the Cyborg framework.

Browse Biopharmaceuticals - Targeted Protein Degradation research →
NEW · MCP server

Ask your AI assistant about C4 Therapeutics, Inc.

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare C4 Therapeutics, Inc. and its top competitor on Cyborg Score”
“What did C4 Therapeutics, Inc. do this quarter?”
“Is C4 Therapeutics, Inc. a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg builds confidence

⚔

Analyst debate, not single-author opinion

Every report is stress-tested by a panel of AI analysts arguing across 11 dimensions. The output is the part of the case that survived pushback.

📊

Recalibrated weekly

The Cyborg Score is recomputed weekly against fresh data. Recent material developments are continuously tracked and surfaced.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The same company gets the same score from any analyst running the framework.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, news flow, and proprietary analyst signals. Read the methodology →

Frequently asked questions

What does C4 Therapeutics, Inc. do?+
C4 Therapeutics is a clinical-stage biopharmaceutical company that develops novel therapeutic candidates to degrade disease-causing proteins. The company is focused on delivering targeted protein degradation science t...
What is C4 Therapeutics, Inc.'s Cyborg Score?+
C4 Therapeutics, Inc. has a Cyborg Score of 5/10 (Mixed). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are C4 Therapeutics, Inc.'s main competitors?+
Named competitors include Targeted Protein Degradation Platform, IMiD-based Degrader, PROTAC Technology. The full competitive landscape is in the AskCyborg report.
How can I get the full C4 Therapeutics, Inc. research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the C4 Therapeutics, Inc. research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track C4 Therapeutics, Inc. over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

Top-scored companies on AskCyborg

The strongest performers across the analyst-debate framework.

9Advantest Corporation9Anthropic9Apple Inc.9Applied Materials, Inc.9Arista Networks9Aritzia Inc.9ASML Holding N.V.9BAE Systems plc9Barrick Mining Corporation9Berkshire Hathaway Inc.